P. Jean-louis, Comment sécuriser les traitements par les biomédicaments ? Bull, Acad. Natle Méd, vol.195, issue.3, pp.679-698, 2011.

C. Jamin, Traitement du lupus érythémateux disséminé par anticorps monoclonaux : un exemple d

A. Schindele, Les anticorps monoclonaux, de la production à l'utilisation en oncologie, Thèse d'exercice en Pharmacie. Faculté de Pharmacie de Nancy, 2009.

H. Watier, De la s??roth??rapie aux anticorps recombinants ????nus????, m??decine/sciences, vol.25, issue.12, pp.999-100, 2009.
DOI : 10.1051/medsci/20092512999

R. Abès, C. Dutertre, and J. Teillaud, Les anticorps : mieux les conna??tre pour mieux s???en servir, m??decine/sciences, vol.25, issue.12, pp.1011-1020, 2009.
DOI : 10.1051/medsci/200925121011

J. Haeuw, V. Caussanel, and A. Beck, Les immunoconjugu??s, anticorps ????arm??s???? pour combattre le cancer, m??decine/sciences, vol.25, issue.12, pp.1046-52, 2009.
DOI : 10.1051/medsci/200925121046

J. Sibilia, Prot??ine de fusion ou anticorps monoclonal, m??decine/sciences, vol.25, issue.12, pp.1033-1041, 2009.
DOI : 10.1051/medsci/200925121033

C. Ortega, Ingénierie de fragments d'anticorps pour l'imagerie in vivo de cancers de la sphère génitale, Thèse de doctorat, 2012.

D. Bellet and V. Dangles-marie, Anticorps humanis??s en th??rapeutique, Médecine/Sciences, pp.1054-1062, 2005.
DOI : 10.1051/medsci/200521121054

A. H. Sharpe, &. Gordon, and J. Freeman, THE B7???CD28 SUPERFAMILY, Nature Reviews Immunology, vol.12, issue.2, pp.116-126, 2002.
DOI : 10.1038/35069118

A. H. Sharpe, &. Gordon, and J. Freeman, THE B7???CD28 SUPERFAMILY, Nature Reviews Immunology, vol.12, issue.2, pp.116-126, 2002.
DOI : 10.1038/35069118

J. Teillaud, Les biothérapies anti-lymphocyte B : une histoire d'anticorps

C. Webconf-du, Club Rhumatismes et inflammations) Centre de, Recherche des Cordeliers (CRC) INSERM UMRS, vol.872

A. M. Scott, J. P. Allison, and J. D. Wolchok, Monoclonal antibodies in cancer therapy, Cancer immunity, vol.12, issue.1, p.14, 2012.

P. Michael, D. P. Cancro, M. A. Cruz, and . Khamasht, The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus, J Clin Invest, 2009.

S. Antoniu and . Mogamulizumab, C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma, Curr Opin Mol Ther, vol.12, issue.6, pp.770-779, 2010.

L. 'histoire-de-la-vaccination, Sous la direction d, 1996.

F. Schleich, M. Manise, and R. Louis, Omalizumab (Xolair®) dans le traitement de l'asthme allergique persistant sévère, Rev Med Liège, vol.64, pp.5-6, 2009.

G. Paintaud, M. Diviné, and P. Lechat, Anticorps monoclonaux ?? usage th??rapeutique : sp??cificit??s du d??veloppement clinique, ??valuation par les agences, suivi de la tol??rance ?? long terme, Th??rapie, vol.67, issue.4, pp.319-327, 2012.
DOI : 10.2515/therapie/2012043

V. I. Mistretta, E. Cavalier, J. Collette, and J. P. Chapelle, Production des anticorps monoclonaux, Rev Med Liège, vol.64, issue.2, pp.5-6, 2009.

I. Lefkovits and B. Pernis, Immunological Methods: v.3. Edition Academic Press Novembre, 1985.

M. Moutschen and A. J. Scheen, Bases immunologiques a la compréhension du concept d'anticorps monoclonal, Rev Med Liège, vol.64, pp.5-6, 2009.

A. J. Scheen, Nomenclature internationale des différents types d'anticorps monoclonaux, Rev Med Liège, vol.64, pp.5-6, 2009.

A. J. Scheen, Nouvelles avancées dans l'utilisation des anticorps monoclonaux en thérapeutique, Rev Med Liège, vol.64, pp.5-6, 2009.

J. Sibilia, Protéine de fusion ou anticorps monoclonal quel biomédicament choisir dans une maladie inflammatoire ? Médecine, Sciences, vol.25, pp.1033-1041, 2009.
DOI : 10.1051/medsci/200925121033

G. Jochen and . Salfeld, Isotype selection in antibody engineering, Nature Biotechnolog, vol.25, 2007.

A. J. Drs, D. W. Meulenbroek, and . Zeijlemaker, Human IgG Subclasses: Useful diagnostic markers for immunocompetence

G. Leonard and . Presta, Molecular engineering and design of therapeutic antibodies, Current Opinion in Immunology, vol.20, pp.460-470, 2008.

T. Shantha and R. , Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Current Opinion in Immunology, vol.20, pp.471-478, 2008.

S. Kozlowski and P. Swann, Current and future issues in the manufacturing and development of monoclonal antibodies, Advanced Drug Delivery Reviews, vol.58, issue.5-6, pp.707-722, 2006.
DOI : 10.1016/j.addr.2006.05.002

E. Elizabeth, . Hood, L. Susan, . Woodard, E. Michael et al., Monoclonal antibody manufacturing in transgenic plants -myths and realities, Current Opinion in Biotechnology, vol.13, pp.630-635, 2002.

S. S. Farid, Process economics of industrial monoclonal antibody manufacture, Journal of Chromatography B, vol.848, issue.1, pp.8-18, 2007.
DOI : 10.1016/j.jchromb.2006.07.037

O. Spadiut, S. Capone, F. Krainer, A. Glieder, and C. Herwig, Microbials for the production of monoclonal antibodies and antibody fragments, Trends in Biotechnology, vol.32, issue.1, pp.1-7, 2013.
DOI : 10.1016/j.tibtech.2013.10.002

P. Marie-paule, L. Mylène, W. , T. Duc, H. Christelle et al., Présentation à la surface de phages filamenteux : les multiples applications du phage display. Last updated: 10, 2013.

P. Owen and . Ward, Production of recombinant proteins by filamentous fungi, Biotechnology Advances, vol.30, pp.1119-1139, 2012.

G. Graziani, L. Tentori, and P. Navarra, Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer, Pharmacological Research, vol.65, issue.1, pp.9-22, 2012.
DOI : 10.1016/j.phrs.2011.09.002

A. Ciurea, Les anticorps monoclonaux dans le traitement des maladies rhumatismales auto-immunes, Curriculum Forum Med Suisse, vol.8, issue.10, pp.182-186, 2008.

P. Chames and D. Baty, Ingénierie des anticorps monoclonaux. BIOFUTUR 288 ? MAI, 2008.

B. Haraoui and V. Bykerk, Etanercept in the treatment of rheumatoid arthritis, Therapeutics and Clinical Risk Management, vol.3, issue.1, pp.99-105
DOI : 10.2147/tcrm.2007.3.1.99

S. Houel, N- and O-Glycosylation Analysis of Etanercept Using Liquid Chromatography and Quadrupole Time-of-Flight Mass Spectrometry Equipped with Electron-Transfer Dissociation Functionality, Analytical Chemistry, vol.86, issue.1, pp.576-584, 2014.
DOI : 10.1021/ac402726h

A. Beck, Analytical characterization of biosimilar antibodies and Fc-fusion proteins, TrAC Trends in Analytical Chemistry, vol.48, pp.81-95, 2013.
DOI : 10.1016/j.trac.2013.02.014

M. Willrich, D. Murray, and M. Snyder, TNF Inhibitors: clinical utility in autoimmune diseases, Transl Res, 2014.

K. Bouzid, N. Bedairia, and M. Marty, Anticorps monoclonaux th??rapeutiques en canc??rologie, Pathologie Biologie, vol.60, issue.4, pp.223-228, 2012.
DOI : 10.1016/j.patbio.2012.05.008

H. I. Hurwitz, Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the Avastin?? Registry ??? Investigation of Effectiveness and Safety (ARIES) Observational Cohort Study, Clinical Oncology, vol.26, issue.6, pp.323-332, 2014.
DOI : 10.1016/j.clon.2014.03.001

G. Socié and N. Varoqueaux, Régis Peffault de Latour. Anticorps monoclonal anti-C5 (éculizumab) dan l'hémoglobinurie paroxystique nocturne

C. Parker, Eculizumab for paroxysmal nocturnal haemoglobinuria, The Lancet, vol.373, issue.9665, pp.759-67, 2009.
DOI : 10.1016/S0140-6736(09)60001-5

D. Kathy, G. L. Mccoy, and . Gros, The role of CTLA-4 in the regulation of T cell immune responses, Immunology and Cell Biology, vol.77, pp.1-10, 1999.

C. Magdelaine-beuzelin, Structure???function relationships of the variable domains of monoclonal antibodies approved for cancer treatment, Critical Reviews in Oncology/Hematology, vol.64, issue.3, pp.210-225, 2007.
DOI : 10.1016/j.critrevonc.2007.04.011

URL : https://hal.archives-ouvertes.fr/hal-00193362

T. Funakoshi, Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis, Cancer Treatment Reviews, vol.40, issue.10, 2014.
DOI : 10.1016/j.ctrv.2014.09.002

G. Zalcman, Voie de l???EGFR et m??canisme d???action des inhibiteurs de tyrosine kinase, Revue de Pneumologie Clinique, vol.63, issue.1, pp.2-5, 2007.
DOI : 10.1016/S0761-8417(07)90097-8

E. Martinelli, R. De-palma, M. Orditura, F. D. Vita, and F. Ciardiello, Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy, Clinical & Experimental Immunology, vol.24, issue.2, pp.1-9
DOI : 10.1111/j.1365-2249.2009.03992.x

T. Fehr and R. P. Wüthrich, Le rôle des anticorps monoclonaux dans la transplantation d'organes, Forum Med Suisse, vol.8, issue.11, pp.204-209, 2008.

J. Goebel, E. Stevens, K. Forrest, and T. L. Roszman, Daclizumab (Zenapax??) inhibits early interleukin-2 receptor signal transduction events, Transplant Immunology, vol.8, issue.3
DOI : 10.1016/S0966-3274(00)00021-6

T. Vu, M. X. Sliwkowski, and F. X. Claret, Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1846, issue.2
DOI : 10.1016/j.bbcan.2014.07.007

K. Lippuner, Les anticorps monoclonaux dans le traitement de l'ostéoporose: bientôt déjà dans la pratique quotidienne, Forum Med Suisse, vol.8, pp.12-13229, 2008.

G. J. Weiner, Rituximab: Mechanism of Action, Seminars in Hematology, vol.47, issue.2, pp.115-123, 2010.
DOI : 10.1053/j.seminhematol.2010.01.011

L. Klotz, S. G. Meuth, and H. Wiendl, Immune mechanisms of new therapeutic strategies in multiple sclerosis???A focus on alemtuzumab, Clinical Immunology, vol.142, issue.1, pp.25-30, 2012.
DOI : 10.1016/j.clim.2011.04.006

K. Ishitsuka and K. Tamura, Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. The Lancet Oncology, pp.517-526, 2014.

D. Seimetz, H. Lindhofer, and C. Bokemeyer, Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM??anti-CD3) as a targeted cancer immunotherapy, Cancer Treatment Reviews, vol.36, issue.6, pp.458-467, 2010.
DOI : 10.1016/j.ctrv.2010.03.001

. Calabresi, Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients, Journal of Neuroimmunology, vol.235, pp.70-76, 2011.

J. T. Bates, Escape from neutralization by there spiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein, Virology, vol.454, pp.455139-144, 2014.

D. A. Fitzgerald, Preventing RSV bronchiolitis in vulnerable infants: The role of palivizumab, Paediatric Respiratory Reviews, vol.10, issue.3, pp.143-147, 2009.
DOI : 10.1016/j.prrv.2009.06.002

P. Pollack and J. R. Groothuis, Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV, Journal of Infection and Chemotherapy, vol.8, issue.3, pp.201-206, 2002.
DOI : 10.1007/s10156-002-0178-6

K. Poon, Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability, Toxicology and Applied Pharmacology, vol.273, issue.2, pp.298-313, 2013.
DOI : 10.1016/j.taap.2013.09.003

L. Phillips, Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2_ Breast Cancer, Clinical Breast Cancer, vol.11, issue.5, pp.275-82

W. W. Wong, Image-Guided Radiotherapy for Prostate Cancer: A Prospective Trial of Concomitant Boost Using Indium-111???Capromab Pendetide (ProstaScint) Imaging, International Journal of Radiation Oncology*Biology*Physics, vol.81, issue.4, pp.423-429, 2011.
DOI : 10.1016/j.ijrobp.2011.01.048

D. and B. Sodee, Update on Fused Capromab Pendetide Imaging of Prostate Cancer, Clinical Prostate Cancer, vol.3, issue.4, pp.230-238, 2005.

H. Neil and . Bander, Technology Insight: monoclonal antibody imaging of prostate cancer, Nature Clinical Practice Urology, vol.3, pp.216-225, 2006.

Y. Renaudineau, M??canismes de l???action des anticorps monoclonaux anti-CD20 et surveillance biologique de leurs effets, Revue du Rhumatisme, vol.76, issue.9, pp.826-832, 2009.
DOI : 10.1016/j.rhum.2009.03.009

P. Goupille, Quel intérêt du dosage pour la pratique des biomédicaments et des anticorps induits ? réalités en rhumatologie, 2012.

S. Rizzo, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treatment Reviews, vol.36, issue.3, pp.56-61, 2010.
DOI : 10.1016/S0305-7372(10)70021-9

J. G. Elvin, R. G. Couston, and C. F. Van-der-walle, Therapeutic antibodies: Market considerations, disease targets and bioprocessing, International Journal of Pharmaceutics, vol.440, issue.1, pp.83-98, 2013.
DOI : 10.1016/j.ijpharm.2011.12.039

A. L. Nelson, E. Dhimolea, and J. M. Reichert, Development trends for human monoclonal antibody therapeutics, Nature Reviews Drug Discovery, vol.25, issue.10, pp.767-774, 2010.
DOI : 10.1038/nrd3229

M. Simeoni and C. Chen, Mechanistic model for the involvement of the neonatal Fc receptor in IgG disposition, Clinical Pharmacology Modelling and Simulation

G. Jochen and . Salfeld, Isotype selection in antibody engineering, Nature Biotechnology, vol.25, issue.12, 2007.

H. Bouchard, C. Viskov, and C. Garcia-echeverria, Antibody???drug conjugates???A new wave of cancer drugs, Bioorganic & Medicinal Chemistry Letters, vol.24, issue.23, pp.5357-5363, 2014.
DOI : 10.1016/j.bmcl.2014.10.021

G. Sylvain and . Richard-nathalie, Utilisation des anti-VEGF dans le traitement local de la DMLA et autres rétinopathies. 13 février 2014 Séminaire Conseil d'Administration ANSM. www.ansm.fr -[87] https, 2014.